Navigation Links
MR spectroscopy identifies breast cancer, reduces biopsies

OAK BROOK, Ill.Proton magnetic resonance spectroscopy (H MRS) used in conjunction with magnetic resonance imaging (MRI) can aid radiologists in diagnosing breast cancer while reducing the number of false-positive results and invasive biopsies, according to a study focusing on non-mass enhancing breast lesions. The study, conducted at Memorial Sloan-Kettering Cancer Center in New York City, appears in the October issue of the journal Radiology.

All of the cancers present in this study were identified with MR spectroscopy, said the studys lead author, Lia Bartella, M.D., director of breast imaging at Eastside Diagnostic Imaging in New York City.

The American Cancer Society estimates that 212,920 women will be diagnosed with breast cancer in the United States this year. MRI is playing an increasingly important role in the screening of women at high risk for breast cancer. However, while MRI depicts more abnormal findings than other breast screening procedures, it is not 100 percent accurate in distinguishing benign from malignant lesions, resulting in a large number of breast biopsy procedures recommended on the basis of imaging findings. Currently, approximately 80 percent of breast lesions biopsied are found to be benign.

Non-mass enhancing lesions are characterized by enhancement of an area that is not a mass or lump and may extend over large or small regions. Non-mass lesions occur with benign hormonal changes, but can also signify malignancy. Biopsy is often required to distinguish benign non-mass lesions from cancer.

With MR spectroscopy, which adds only 10 minutes to a standard MRI exam, the radiologist is able to see the chemical make-up of a tumor. In most cases, the results indicate whether or not the lesion is cancerous without the need for biopsy.

Non-mass enhancing lesions frequently pose a dilemma to the radiologist when evaluating the breast for the presence of cancer, especially in premenopausal women, Dr. Bartella said. Potentially, the use of proton MR spectroscopy may help decrease the number of benign biopsies for non-mass enhancing lesions.

For the study, Dr. Bartella and colleagues performed H MRS on 32 non-mass enhancing breast lesions in 32 women, age 20 to 63. Twenty-five of the patients had lesions that had been labeled suspicious at MRI.

H MRS can provide radiologists with chemical information about a lesion by measuring the levels of choline compounds, which are markers of an active tumor. In the study, positive choline findings were present in 15 of 32 lesions, including all 12 cancers, giving H MRS a specificity of 85 percent and a sensitivity of 100 percent. If only the lesions with positive choline findings had been biopsied, 17 (68 percent) of 25 lesions may have been spared invasive biopsies and none of the cancers would have been missed.

By performing MR spectroscopy of the suspicious lesion after an MRI scan, we can noninvasively see which tumors show elevated choline levels and are likely malignant, Dr. Bartella said. This chemical information added to the information provided by MRI can eliminate the need for biopsy to find out what the lesion is made of.

Dr. Bartella hopes that in the future, MR spectroscopy will be incorporated into routine diagnostic breast MRI procedures, significantly decreasing the need for needle biopsies.


Contact: Linda Brooks
Radiological Society of North America

Related medicine news :

1. Nuclear magnetic resonance spectroscopy aids in mapping protein structure
2. Preterm Babies Benefited from a New NI Spectroscopy
3. A New Form of Spectroscopy to Assess Reproductive Potential of Embryo
4. Research identifies trigger that sets of Huntingtons disease
5. Research Identifies The Causes Of Snoring
6. New Test Identifies Candidates For Cardiac Defibrillator
7. Research Identifies Osteoporosis Controlling Protein
8. New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer
9. Study Identifies Mechanism Which May Help Tamoxifen Work Better
10. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
11. Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into its ... 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... NE (PRWEB) , ... November 26, 2015 , ... Jobs ... searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group ... during the month of October 2015 among those searching for healthcare jobs through the ...
(Date:11/26/2015)... ... 2015 , ... WorldCare International, Inc., the first company to ... Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation of ... 2015. The conference was held at the Hawaii Convention Center in Honolulu, Oahu, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
(Date:11/25/2015)... 2015 On Tuesday, November 24, 2015, ... against Wright Medical Technology, Inc. for product liability ... hip implant device, awarded $11 million in favor ... trial and three days of deliberations, the jury ... defectively designed and unreasonably dangerous, and that Wright ...
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
Breaking Medicine Technology: